The european hospital exemption clause-new option for gene therapy?

Human Gene Therapy

Volumn 23, Issue 1, 2012, Pages 7-12

  Buchholz, Christian J ^a   Sanzenbacher, Ralf ^a   Schüle, Silke ^a  

^a PAUL EHRLICH INSTITUT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CELL THERAPY; DRUG EFFICACY; DRUG LEGISLATION; DRUG MARKETING; DRUG SAFETY; EUROPEAN UNION; GENE THERAPY; OUTCOME ASSESSMENT; PHYSICIAN; REVIEW;

CELL TRANSPLANTATION; CLINICAL TRIALS AS TOPIC; CONSUMER PRODUCT SAFETY; DRUG INDUSTRY; EUROPE; EUROPEAN UNION; GENE THERAPY; GUIDELINES AS TOPIC; HUMANS; LEGISLATION, HOSPITAL; MARKETING; TISSUE ENGINEERING;

EID: 84855863541     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2011.2529     Document Type: Review

References (16)

1. Anliker, B., Longhurst, S., and Buchholz, C.J. (2010). Environmental risk assessment for medicinal products containing genetically modified organisms. Bundesgesundheitsblatt Ge-sundheitsforschung Gesundheitsschutz 53, 52-57.
2. Bainbridge, J.W., Smith, A.J., Barker, S.S., et al. (2008). Effect of gene therapy on visual function in Leber's congenital amau-rosis. N. Engl. J. Med. 358, 2231-2239. (Pubitemid 351724452)
3. Boztug, K., Schmidt, M., Schwarzer, A., et al. (2010). Stem-cell gene therapy for the Wiskott-Aldrich syndrome. N. Engl. J. Med. 363, 1918-1927.
4. Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C.C., et al. (2009). Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 326, 818-823.
5. Cartier, N., Hacein-Bey-Abina, S., Von Kalle, C., et al. (2010). [Gene therapy of x-linked adrenoleukodystrophy using he-matopoietic stem cells and a lentiviral vector]. Bull. Acad. Natl. Med. 194, 255-264; discussion 264-268.
6. Cavazzana-Calvo, M., Payen, E., Negre, O., et al. (2010). Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia. Nature 467, 318-322.
7. Gaspar, H.B., Bjorkegren, E., Parsley, K., et al. (2006). Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning. Mol. Ther. 14, 505-513. (Pubitemid 44339393)
8. Gaspar, H.B., Cooray, S., Gilmour, K.C., et al. (2010). Long-term persistence of a polyclonal T cell repertoire after gene therapy for X-linked severe combined immunodeficiency. Sci. Transl. Med. 3, 97ra79.
9. Gaspar, H.B., Cooray, S., Gilmour, K.C., et al. (2011). Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction. Sci. Transl. Med. 3, 97ra80.
10. Guo, J., and Xin, H. (2006). Chinese gene therapy. Splicing out the West? Science 314, 1232-1235. (Pubitemid 44846373)
11. Naldini, L. (2011). Ex vivo gene transfer and correction for cell-based therapies. Nat. Rev. Genet. 12, 301-315.
12. Sanzenbacher, R., Dwenger, A., Schuessler-Lenz, M., et al. (2007). European regulation tackles tissue engineering. Nat. Bio-technol. 25, 1089-1091. (Pubitemid 47538102)
13. Schü le, S., Renner, M., Longhurst, S., and Narayanan, G. (2010). Regulatory requirements for clinical trial and marketing au thorisation application for gene therapy medicinal products. Bundesgesundheitsblatt Gesundheitsforschung Ge-sundheitsschutz 53, 30-37.
14. Sheridan, C. (2011). Gene therapy finds its niche. Nat. Bio-technol. 29, 121-128.
15. Simonelli, F., Maguire, A.M., Testa, F., et al. (2010). Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol. Ther. 18, 643-650.
16. Thrasher, A.J., Gaspar, H.B., Baum, C., et al. (2006). Gene therapy: X-SCID transgene leukaemogenicity. Nature 443, E5-E-6; discussion E6-E7. (Pubitemid 44435140)